An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Trial Profile

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 05 May 2014 The US FDA has approved Alexion Pharmaceuticals' supplemental Biologics License Application (sBLA) providing regular approval for eculizumab; regular approval includes data from this study.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top